View Author
scopus: 35413234400

Heijtink, R.A.

( R.A. Heijtink)


hbsag hepatitis vaccine antibody anti-hb patient genotype binding assay virus peptide treatment serum mutation hbeag sequence response sample hepatitis b virus study hepatitis b heijtink infection tuvirumab level phase 1 ff 4 inhibition hepatitis b vaccine antigen result epitope signal core promoter mutations subtype vaccination conjugate table hbv genotypes f 4-7b precore plasma-derived promoter therapy hepatitis c virus virol interferon surface plasma reference region experiment variant change hansenula-derived serum anti-hbs hb-vax analysis complex motif interferon treatment adw 2 hbsag /adw number hbv genotype selection assay speci month yeast preparation core promoter anti-hbs antibodies hbs.ot activity difference hbsag /tuvirumab complexes binding assay hbv dna netherland baseline




9 Most Recent Publications

Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance (Article)
Hou, J. Schilling, R. Janssen, H.L.A. Hansen, B.E. Heijtink, R.A. Sablon, E. Williams, R. Lau, G.K.K. Schalm, S.W. Naoumov, N.V.
2007-08-01
Hepatitis B surface antigen (HBsAg) derived from yeast cells (Hansenula polymorpha) used to establish an influence of antigenic subtype (adw2, adr, ayw3) in measuring the immune response after vaccination. (Article)
Heijtink, R.A. Bergen, P. van Melber, K. Janowicz, Z.A. Osterhaus, A.D.M.E.
2002-05-22
Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine. (Article)
Heijtink, R.A. Kruining, J. Bergen, P. van Rave, S. de Hattum, J. van Schutten, M. Osterhaus, A.D.M.E.
2002-02-11
Anti-HBs after hepatitis B immunization with plasma-derived and recombinant DNA-derived vaccines: binding to mutant HBsAg. (Article)
Heijtink, R.A. Bergen, P. van Roosmalen, M.H. van Paulij, W.P. Schalm, S.W. Osterhaus, A.D.M.E. Sünnen, C.M.G.
2001-06-14
Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: Monitoring of serum TUVIRUMAB in immune complexes. (Article)
Heijtink, R.A. Osterhaus, A.D.M.E. Man, R.A. de Bergen, P. van Östberg, L. Nunen, A.B. van
2001-01-01
Anti-HBs characteristics after hepatitis B immunisation with plasma-derived and recombinant DNA-derived vaccines. (Article)
Heijtink, R.A. Bergen, P. van Paulij, W.P. Man, R.A. de Osterhaus, A.D.M.E.
2000-02-14
Characteristics of early phase of chronicity in acute hepatitis B infection. (Article)
Heijtink, R.A. Paulij, W. Roosmalen, M.H. van Hellings, J.A. Schalm, S.W. Osterhaus, A.D.M.E. Niesters, H.G.M.
1999-01-01
Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture (Article)
Heijtink, R.A. Kruining, J. Wilde, G.A. de Balzarini, J. Clercq, E. de Schalm, S.W.
1994-01-01
Sequence analysis of the 5' untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands (Article)
Kleter, G.E.M. Doorn, L-J. van Brouwer, J.T. Schalm, S.W. Heijtink, R.A. Quint, W.G.V.
1994-01-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile